Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 877

1.

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.

Blood. 2003 Jan 1;101(1):270-7.

2.

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG.

Nat Med. 2001 Apr;7(4):444-51.

PMID:
11283671
3.

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.

Elsässer A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G.

Oncogene. 2003 Aug 28;22(36):5646-57.

PMID:
12944913
4.

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.

Lo Coco F, Pisegna S, Diverio D.

Haematologica. 1997 May-Jun;82(3):364-70. Review.

5.

The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.

Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD.

Oncogene. 1999 Mar 4;18(9):1701-10.

6.
7.

Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia.

Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM, Chang KS.

Eur J Haematol. 1998 Apr;60(4):217-25.

PMID:
9579874
8.

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

Licht JD.

Oncogene. 2001 Sep 10;20(40):5660-79. Review. No abstract available.

9.

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW.

Nat Med. 2002 Jul;8(7):743-50.

PMID:
12091906
10.

Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.

Fliegauf M, Stock M, Berg T, Lübbert M.

Oncogene. 2004 Dec 2;23(56):9070-81.

PMID:
15489901
11.

Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.

Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y.

Blood. 1996 Jun 1;87(11):4789-96.

12.
13.
14.
15.

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.

Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE.

Nat Med. 2006 Aug;12(8):945-9.

PMID:
16892037
16.

AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.

Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD.

Blood. 2000 Dec 1;96(12):3939-47.

17.

AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression.

Yeh JR, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT.

Development. 2008 Jan;135(2):401-10.

18.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402.

19.

AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.

Choi Y, Elagib KE, Goldfarb AN.

Crit Rev Eukaryot Gene Expr. 2005;15(3):207-16. Review.

PMID:
16390317
20.

Supplemental Content

Support Center